Gene Therapy for LCA10: The Brilliance Phase 1/2 Clinical Trial Of AGN-151587 (EDIT-101) Update

The Brilliance Phase 1/2 Clinical Trial Of AGN-151587 (EDIT-101) For The Treatment Of LCA10

Description
This is an open-label, single ascending dose study of AGN-151587 (EDIT-101) in adult and pediatric (ie, ages 3 to 17) participants with LCA10-IVS26. Approximately 18 participants will be enrolled in up to 5 cohorts to evaluate up to 3 dose levels of AGN-151587 in this study. AGN-151587 is a novel gene editing product designed to eliminate the mutation on the CEP290 gene that results in the retinal degeneration that defines LCA10-IVS26.

Single-dose of AGN-151587 administered by subretinal injection surgery
Participants will receive a single dose of AGN-151587 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Primary Outcome Measure

Frequency of Adverse Events related to AGN-151587
Number of participants experiencing procedural related adverse events
Incidence of dose limiting toxicities

Secondary Outcome Measures

Maximum tolerated dose as determined by the occurrence of dose-limiting toxicities
Change from baseline in Mobility course score
Testing the subjects visual function by having the subject walk through obstacle courses.
Change from baseline in LogMAR measurement of BCVA
Change from baseline in pupillary response

(More on clinicaltrials.gov)

Update March 2020

Dosing Of First Patient In Landmark Phase 1/2 Clinical Trial Of CRISPR Medicine AGN-151587 (EDIT-101) For The Treatment Of LCA10

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN-151587 (EDIT-101) at Oregon Health & Science University (OHSU) Casey Eye Institute, a world-recognized academic eye center.

Therapeutic Approach:

EDIT-101 (also known as AGN-151587) is tested for its ability to remove a point mutation in the CEP290 gene, which causes type 10 of the retinal degenerative disease Leber congenital amaurosis (LCA). The schematics are given below

Non-Clinical Evidence of Correction of CEP290 Mutation by CRISPR/Cas9 system

"Key to this therapeutic, we identified a pair of Staphylococcus aureus Cas9 guide RNAs that were highly active and specific to the human CEP290 target sequence. In vitro experiments in human cells and retinal explants demonstrated the molecular mechanism of action and nuclease specificity. Subretinal delivery of EDIT-101 in humanized CEP290 mice showed rapid and sustained CEP290 gene editing. A comparable surrogate non-human primate (NHP) vector also achieved productive editing of the NHP CEP290 gene at levels that met the target therapeutic threshold, and demonstrated the ability of CRISPR/Cas9 to edit somatic primate cells in vivo. "
Publication: Nature Medicine:25, pages229–233(2019)

Reference

www.clinicaltrial.gov

Editas Medicine

Allergan plc

Carbohydrate Metabolism: MCQs and answers on Glycolysis & Gluconeogenesis

MCQ on Glycolysis & Gluconeogenesis 1) Which of the following enzyme is not involved in galactose metabolism? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 2) Which of the following enzyme is defective in galactosemia (type I) - a fatal genetic disorder in infants? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 3) In the liver, the accumulation of which of the following metabolite attenuates the inhibitory of ATP on phosphofructokinase? a) Glucose-6-Phosphate b) Citrate c) Fructose-1,6-Bisphosphate d) Fructose-2,6-Bisphosphate 4) Mutation in which of the following enzymes leads to a glycogen storage disease known as "Tarui’s disease"? a) Glucokinase b) Phosphofructokinase c) Phosphoglucomutase d) Pyruvate Kinase 5) E...

Multiple Choice Questions (MCQs) on Diabetes Mellitus: Pathogenesis, Diagnosis and Treatment

MCQs on Diabetes mellitus 1) Diabetes mellitus is a disorder characterized by hyperglycemia. Which of the following is not the common characteristic features of type 2 diabetes mellitus ? a) Impaired insulin secretion b) Increased Insulin resistance c) Diabetic ketoacidosis d) Excessive hepatic glucose production 2) Which of the following are the characteristic features of type 1 diabetes mellitus? a) Type 1 diabetes is caused by an absolute deficiency of insulin. b) Type 1 diabetes is associated with the autoimmune destruction of beta cells. c) Patients with uncontrolled type 1 diabetes present with diabetic ketoacidosis d) All of the above 3) Which of the following serum measurements are not used for the diagnosis of diabetes mellitus? a) Fasting blood glucose d) Postprandial blood glucose c) Insulin ...

MCQs on Superficial and Cutaneous Mycoses-Dermatophytes: Medical Mycology

Multiple Choice Questions on Superficial and Cutaneous Fungal Infections 1. All of the following are examples of common superficial mycoses, EXCEPT ? a) Aspergillosis b) Candidiasis c) Tinea versicolor d) Tinea nigra 2. Which of the following statement regarding Tinea nigra infection is NOT correct? a) Most prevalent in the tropical and subtropical region b) Symptoms include pigmented macules on palm and soles c) Trycophyton spp is the causative fungi d) Common specimen is skin scrapings 3. The fungi Trichosporon commonly causes superficial infection of hair also called white piedra. Which of the following species of Trichosporon causes scalp hair white piedra ? a) T. ovoides b) T. inkin c) T. asahii d) None of the above 4. All of the following are the characteristics of cutaneous mycoses, EXCEPT ? a) The infection of hair, skin, and nails b) The common cause of ringworm in humans only c) Candida spp is associated with the infection d) The keratinize...

BIOCHEMISTRY, BIOMEDICINE & PHARMACEUTICS

Search This Blog